2026 · 3rd Quarter (July 1 - Sep 30)

ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION

Filed by THE WASHINGTON TAX & PUBLIC POLICY GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 16, 2026
Income: $400,000.00
Expenses: Not reported
Registrant: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Client: ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION
Filing UUID: c8bb63b1-74d8-47ad-bf98-08ecd70f2b05
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

TAX · Taxation/Internal Revenue Code

Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations, agreements, implementation, and reporting related to the taxation of global income. Issues related to the taxation of intellectual property income. Issues related to foreign country tax administration and extraterritorial taxes. Issues related to IRC sections 11, 41 and 174, 45C, 55, 56A, and 59, 59A, 163(j), 250, 951A, 954(d) and 954(e), and 960(d)(2). (H.R. 10431)

Literal federal measure citations: H.R. 10431

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.